Your browser doesn't support javascript.
loading
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton, Mike I; Eve, Paul D; Hayes, Angela; Henley, Alan T; Valenti, Melanie R; De Haven Brandon, Alexis K; Box, Gary; Boxall, Kathy J; Tall, Matthew; Swales, Karen; Matthews, Thomas P; McHardy, Tatiana; Lainchbury, Michael; Osborne, James; Hunter, Jill E; Perkins, Neil D; Aherne, G Wynne; Reader, John C; Raynaud, Florence I; Eccles, Suzanne A; Collins, Ian; Garrett, Michelle D.
Affiliation
  • Walton MI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Eve PD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Hayes A; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Henley AT; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Valenti MR; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • De Haven Brandon AK; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Box G; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Boxall KJ; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Tall M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Swales K; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Matthews TP; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • McHardy T; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Lainchbury M; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Osborne J; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Hunter JE; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK.
  • Perkins ND; Institute for Cell and Molecular Biosciences, Medical School, Newcastle University, Newcastle Upon Tyne, UK.
  • Aherne GW; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Reader JC; Sareum Ltd, Cambridge, UK.
  • Raynaud FI; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Eccles SA; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Collins I; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
  • Garrett MD; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Oncotarget ; 7(3): 2329-42, 2016 Jan 19.
Article de En | MEDLINE | ID: mdl-26295308
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrazines / 4-Amino-pyridine / Lymphome B / Protéines proto-oncogènes p21(ras) / Protéines proto-oncogènes c-myc / Carcinome pulmonaire non à petites cellules / Tests d'activité antitumorale sur modèle de xénogreffe / Checkpoint kinase 1 / Tumeurs du poumon Type d'étude: Clinical_trials Limites: Animals / Humans Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Pyrazines / 4-Amino-pyridine / Lymphome B / Protéines proto-oncogènes p21(ras) / Protéines proto-oncogènes c-myc / Carcinome pulmonaire non à petites cellules / Tests d'activité antitumorale sur modèle de xénogreffe / Checkpoint kinase 1 / Tumeurs du poumon Type d'étude: Clinical_trials Limites: Animals / Humans Langue: En Journal: Oncotarget Année: 2016 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: États-Unis d'Amérique